Jaguar Health, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jaguar Health, Inc. (Nasdaq: JAGX) on December 15, 2020, covering events occurring between December 4, 2020, and December 18, 2020. The Company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, or debt levels. The report focuses exclusively on capital structure changes involving equity issuance.
Material Changes
The Company executed unregistered sales of equity securities through a privately negotiated exchange agreement with a holder of Series D Perpetual Preferred Stock. Between December 4, 2020, and December 18, 2020, the Company issued an aggregate of 11,628,787 shares of Common Stock. This issuance represented more than 5% of the Company's issued and outstanding shares of Common Stock as last reported in the November 16, 2020 Form 10-Q.
- December 15, 2020: Issued 6,060,606 shares of Common Stock in exchange for 250,000 shares of Preferred Stock.
- December 16, 2020: Issued 5,568,181 shares of Common Stock in exchange for 245,000 shares of Preferred Stock.
The effective price per share was equal to the market price, defined as the Minimum Price under Nasdaq Listing Rule 5635(d). These transactions were conducted in reliance on the exemption from registration provided under Section 3(a)(9) of the Securities Act of 1933.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding future guidance, outlook, or specific risks beyond the standard disclosure of the equity exchange. No unusual items or contingencies were reported in this document.
Key Facts for Investor Verification
- Verify the total number of outstanding shares post-transaction to confirm the dilution impact exceeds 5%.
- Confirm the specific "Minimum Price" under Nasdaq Listing Rule 5635(d) used to value the exchanged shares on December 15 and 16, 2020.
- Review the remaining balance of Series D Perpetual Preferred Stock following the exchange of 495,000 shares.
- Check subsequent filings for any registration statements required to register the newly issued Common Stock for public trading.